Date clarification: Today is Tuesday, August 4, 2026. The stated August 4, 2026 earnings event is therefore today, not tomorrow. This preview is framed as a pre-results note using the company’s prior guidance and information available through the August 3 market close.
AMETEK enters 2Q26 earnings with substantial operating momentum. In 1Q, it delivered 11% sales growth, 5% organic growth, 13% adjusted EPS growth, and a 160 bp expansion in core operating margin. More importantly, orders rose 23% (22% organically) to a record $2.22 billion, producing a record $3.87 billion backlog.
The immediate earnings question is therefore not whether AMETEK can post good numbers—it is whether it can demonstrate that the exceptional 1Q order performance, particularly across aerospace & defense, power, process instrumentation, automation, and semiconductor-related applications, is converting into a sustainably stronger second-half outlook.
Management’s formal 2Q guide calls for:
| Metric | 2Q26 company guidance | 2Q25 actual | Implied y/y change |
|---|---|---|---|
| Sales | “High single digits” growth | $1.78B | Roughly $1.92B–$1.94B, depending on definition |
| Adjusted EPS | $1.96–$2.00 | $1.78 | +10% to +12% |
| Full-year adjusted EPS | $7.94–$8.14 | — | +7% to +10% on comparable basis |
| Full-year organic sales | Mid-single-digit growth | — | Raised in 1Q |
The midpoint of the 2Q EPS guide is $1.98, while the midpoint of full-year guidance is $8.04.
The most important headline beyond EPS will be organic sales. AMETEK’s 1Q reported growth benefited from acquisitions and foreign exchange: organic sales were +5%, while acquisitions and FX supplied the balance of the 11% reported increase.
Investors should focus on whether 2Q organic growth remains around the company’s full-year mid-single-digit objective. The order book supports a constructive outlook, but the mix matters:
A favorable outcome would be EIG organic growth beginning to catch up to its strong bookings, while EMG continues to grow at a healthy rate despite tougher comparisons.
The 1Q book-to-bill was approximately 1.15x ($2.22 billion of orders versus $1.93 billion of sales). That was unusually strong and reflected broad-based demand rather than a single isolated program, although several large orders helped.
Management specifically highlighted strength in:
The key question on the call: Was 1Q’s order strength durable, or did it pull forward demand? Management explicitly said it did not view the 1Q results as meaningful pull-forward. Confirmation through another positive book-to-bill and backlog growth would materially reinforce the 2026 setup.
AMETEK’s investment case depends heavily on its ability to pair modest-to-strong organic growth with operating leverage. In 1Q, core operating margin expanded 160 bp, supported by productivity and particularly strong EMG leverage.
For 2026, management’s framework implies:
That makes margin performance especially important in 2Q. Investors should look for:
A sales beat without margin leverage would be less compelling than an in-line revenue quarter paired with strong margins and a higher full-year earnings outlook.
EIG is the larger segment and is central to the earnings debate. In 1Q, sales rose 11%, but only 2% organically, as recent acquisitions were a meaningful contributor. Operating margin was 29.6% reported; on a core basis, management cited a 40 bp improvement.
The catalyst is orders: EIG organic bookings increased 25% in 1Q, with strength across defense, power, semiconductor, process instrumentation, and materials analysis.
What to watch - Whether order strength converts to better organic sales growth; - Process-instrumentation pipeline and project conversion; - Power/data-center demand; - China and broader Asia trends; - Semiconductor capital-equipment demand; - The pace of margin recovery as acquired businesses are integrated.
EMG was the standout in 1Q: sales increased 13%, including 11% organic growth, while operating income rose 33% and operating margin expanded 380 bp to 25.7%.
The segment benefits from automation, engineered solutions, aerospace & defense, and medical exposure. Management described medical as a little over 20% of company sales and said it grew low double digits in 1Q, led by Paragon, but cautioned that comparisons become tougher through the year.
What to watch - Sustainability of EMG’s exceptional margins; - Aerospace & defense growth and defense-aftermarket demand; - Medical growth cadence versus tougher comparables; - Automation demand and whether the strong 1Q pace normalizes; - First Aviation closing/integration timing and any financial contribution. The acquired defense-and-aviation MRO company has roughly $80 million of annual sales.
AMETEK raised 2026 adjusted-EPS guidance after 1Q to $7.94–$8.14, from $7.87–$8.07 previously. The $0.07 increase was measured relative to an exceptional 1Q order print and a first-quarter adjusted EPS result of $1.97, above the company’s prior $1.85–$1.90 guide.
That creates an asymmetric interpretation:
Management has consistently emphasized prudence because of global macro uncertainty, trade policy, inflation, and tariffs. In its 1Q filing, AMETEK said tariff changes had not materially affected 1Q results, but it was using pricing, supply-chain adjustments, and localized production to mitigate potential effects. The market will want an updated read on whether those mitigation efforts remain sufficient.
AMETEK ended 1Q with $2.2 billion of gross debt, $481 million of cash, and approximately 0.7x net debt/EBITDA. Management stated it could deploy well over $5 billion while retaining an investment-grade credit rating.
The company’s acquisition strategy is a durable part of the thesis:
The call could therefore include valuable commentary on M&A cadence, integration, acquisition margins, and the shape of the pipeline.
At the August 3, 2026 close, AME traded at $243.81.
That premium valuation raises the importance of the qualitative signals: book-to-bill, organic-growth acceleration, margin durability, and the potential for another full-year guidance increase matter more than a narrow quarterly EPS beat.
The pre-earnings stance is constructive, but expectations are not low. AMETEK has unusually strong leading indicators: record orders, record backlog, robust cash conversion, improving process/power demand, and secular tailwinds in defense, data-center power infrastructure, precision technology, and automation.
For a positive reaction, investors likely need three things:
The principal downside risk is not a weak 2Q result relative to the company’s guide. It is a sign that EIG’s order surge is slower to convert into revenue, EMG growth/margins are normalizing more quickly than expected, or tariff and macro pressures are becoming harder to offset through pricing and operational actions.